Abstract
To compare expression level of serum tumor associated materials (TAM) with several conventional serum tumor biomarkers, eg., carcinoembryonic antigen (CEA), carbohydrate antigen19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein(AFP), in selected solid tumors. Patients diagnosed histologically or cytologically with liver, breast, esophageal, gastric, colorectal or pancreatic cancers were enrolled into this study. After diagnosis, the level of TAM was determined by chemical colorimetry, and levels of conventional tumor markers was measured by chemiluminescence methods. A total of 560 patients were enrolled into this study. No statistically significant difference was detected in TAM and the above mentioned tumor biomarkers in terms of their positivity and negativity (P>0.05). Detection of TAM in liver, breast, esophageal, gastric, colorectal, and pancreatic cancer patients demonstrates a good accordance with CEA, CA199, CA153, and AFP, thus suggesting that further study is warranted to verify whether TAM could be a surrogate for these conventional biomarkers.
Highlights
Carcinoembryonicantigen (CEA) is one of the most widely used tumor markers worldwide
Patients diagnosed histologically or cytologically with liver, breast, esophageal, gastric, colorectal or pancreatic cancers were enrolled into this study
The level of tumor associated materials (TAM) was determined by chemical colorimetry, and levels of conventional tumor markers was measured by chemiluminescence methods
Summary
Carcinoembryonicantigen (CEA) is one of the most widely used tumor markers worldwide. Its main application is mostly in gastrointestinal cancers, especially in colorectal malignancy (Duffy, 2001). Because the protein was detected in only cancer and embryonic tissue, it was given the name carcinoembryonic antigen, or CEA. The best established marker is CA 19-9 which is a sialylated Lewis antigen of the MUC1 protein with an overall sensitivity of 80% and specificity of 90% in detection of pancreas cancer (Steinberg, 1990). CA 19-9 may be positive in patients with non malignant diseases including cirrhosis, chronic pancreatitis, cholangitis, as well as other gastrointestinal cancers (Duffy et al, 2010). CA 19-9 is widely used to evaluate patients with suspected pancreas cancer and those undergoing treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
